Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) [Phase 3]

View source ↗

Summary

Phase 3 trial of lixisenatide as monotherapy for type 2 diabetes (GETGOAL-MONO Japan LTS) has completed. The results were posted in December 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Adlyxin (lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-12-21